Leucine/sildenafil/metformin companion diagnostic - NuSirt Biopharma/OWL Metabolomics

Drug Profile

Leucine/sildenafil/metformin companion diagnostic - NuSirt Biopharma/OWL Metabolomics

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NuSirt Biopharma
  • Developer NuSirt Biopharma; One Way Liver Genomics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Non-alcoholic fatty liver disease

Most Recent Events

  • 23 Sep 2016 Investigation in Non-alcoholic fatty liver disease (Diagnosis) in USA (unspecified route)
  • 20 Sep 2016 NuSirt Biopharma and One way liver metabolomics collaborates to develop diagnostic tools for drug, NS 0200
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top